Cover Image

Successful Treatment of Aortic Endocarditis by <i>Achromobacter xylosoxidans</i> with Cefiderocol Combination Therapy in a Non-Hodgkin Lymphoma Patient: Case Report and Literature Review

<i>Achromobacter xylosoxidans</i> is a Gram-negative aerobic opportunistic bacterium, belonging to the order of <i>Burkholderiales</i>, that can cause infections of virtually all body districts in patients with underlying diseases. However, <i>A. xylosoxidans</i>...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gianfranco La Bella (Author), Francesco Salvato (Author), Graziano Antonio Minafra (Author), Irene Francesca Bottalico (Author), Tiziana Rollo (Author), Lucia Barbera (Author), Samantha De Tullio (Author), Gaetano Corso (Author), Sergio Lo Caputo (Author), Rosella De Nittis (Author), Fabio Arena (Author)
Format:	Book
Published:	MDPI AG, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The epidemiology of Stenotrophomonas maltophilia and Achromobacter xylosoxidans infections
by: Shani Zilberman-Itskovich, et al.
Published: (2024)

Achromobacter xylosoxidans Causing Late-onset Sepsis with Pneumonia in a Term Neonate
by: BASANY LAXMAN, et al.
Published: (2022)

Native-valve endocarditis caused by Achromobacter xylosoxidans: a case report and review of literature
by: Caio Godoy Rodrigues, et al.
Published: (2017)

Achromobacter Xylosoxidans an Emerging Opportunistic Nosocomial Pathogen: A Retrospective Study in a Tertiary Care Hospital
by: Sunita Mangesh Bhatawadekar, et al.
Published: (2024)

Uncommon pathogen: Serious manifestation: A rare case of Achromobacter xylosoxidans septic arthritis in immunocompetetant patient
by: Kalpana Tikaram Suryavanshi, et al.
Published: (2015)

Case of recurrent Achromobacter xylosoxidans bacteraemia and PICC (peripherally-inserted central catheter) line infection in an immunocompromised patient
by: Elaine Houlihan, et al.
Published: (2022)

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains
by: Vincent Jean-Pierre, et al.
Published: (2024)

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus
by: Vincent Jean-Pierre, et al.
Published: (2024)

An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics of <i>Achromobacter</i> spp. (Labeled Biochemically or by MAL-DI-TOF MS as <i>A. xylosoxidans</i>), Largely in Patient Groups Other than Those with CF
by: Claudio Neidhöfer, et al.
Published: (2022)

Challenges Facing Two Outbreaks of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
by: Montserrat Rodríguez-Aguirregabiria, et al.
Published: (2024)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Arta Karruli, et al.
Published: (2023)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing <i>Klebsiella pneumoniae</i>
by: Federica Bovo, et al.
Published: (2023)

Brote hospitalario de Achromobacter denitrificans relacionado con el uso de clorhexidina contaminada Achromobacter denitrificans hospital outbreak associated with the use of contaminated chlorhexidine
by: Lina María Echeverri, et al.
Published: (2012)

Achromobacter cluster related to COVID-19 supply chain issues
by: Mary Ellen Scales, et al.
Published: (2024)

Post-ERCP bacteremia caused by <it>Alcaligenes xylosoxidans </it>in a patient with pancreas cancer
by: Akcay Korhan, et al.
Published: (2006)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates
by: Harald Seifert, et al.
Published: (2023)

Cefiderocol for Severe Carbapenem-Resistant <i>A. baumannii</i> Pneumonia: Towards the Comprehension of Its Place in Therapy
by: Emanuele Rando, et al.
Published: (2021)

Prevalence of hypermutator isolates of Achromobacter spp. from cystic fibrosis patients
by: Winnie Ridderberg, et al.
Published: (2020)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
by: Michela Padovani, et al.
Published: (2023)

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals
by: Claudia Alteri, et al.
Published: (2024)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in <i>Acinetobacter baumannii</i>
by: Natalia Kolesnik-Goldmann, et al.
Published: (2023)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
by: Davide Carcione, et al.
Published: (2021)

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Keratitis Is Dependent upon the State of the Corneal Epithelium
by: Eric G. Romanowski, et al.
Published: (2024)

Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Strains: Influence of Bacterial Inoculum
by: Celia García-Rivera, et al.
Published: (2024)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023)

Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. <i>Antibiotics</i> 2021, <i>10</i>, 649
by: Christina König, et al.
Published: (2021)

The solution to drug resistance of Gram-negative bacteria - Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
by: Monirul I. Sajib, et al.
Published: (2023)

Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond
by: Davorka Repac Antić, et al.
Published: (2022)

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
by: Giovanna Travi, et al.
Published: (2024)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022)

Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of <i>Klebsiella pneumoniae</i> ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol
by: Maria Giufrè, et al.
Published: (2024)

Late onset nodular prurigo - the sole and initial manifestation of occult <i>Hodgkin′s disease</i>
by: Mehta Vandana, et al.
Published: (2009)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022)

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
by: Cristina Kirkegaard-Biosca, et al.
Published: (2024)

Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients' Prognosis
by: Antonella Frattari, et al.
Published: (2024)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
by: Gabriele Palermo, et al.
Published: (2023)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
by: Julia Zimmer, et al.
Published: (2021)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022)